Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 1, 2026
Context: The filing incorporates by reference a press release regarding the results of a Phase 2a clinical study for the company's drug candidate, Namodenoson, in the treatment of pancreatic cancer.
Key Financial Metrics
The filing text does not provide specific financial data. This Form 6-K serves as a vehicle to disseminate clinical trial results rather than financial performance. Consequently, the following metrics are not disclosed in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The primary material event reported is the completion of a Phase 2a clinical study for Namodenoson in advanced pancreatic cancer. The study achieved its primary safety endpoint and demonstrated durable survival outcomes. No financial material changes versus prior periods are reported in this text.
Guidance, Outlook, and Risks
Management Commentary: The company highlights the achievement of the primary safety endpoint and durable survival outcomes as significant milestones for Namodenoson in advanced disease.
Outlook: The filing implies continued development of Namodenoson based on these positive results, though specific future timelines or financial guidance are not included in this text.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical development implied by the study reporting.
Investor Verification Checklist
- Verify the full details of the Phase 2a study design, patient population, and statistical significance of the "durable survival outcomes" in the attached Exhibit 99.1 press release.
- Confirm the specific definition of the "primary safety endpoint" achieved.
- Review the company's most recent Form 20-F or quarterly reports for current cash runway and liquidity status, as this filing contains no financial data.
- Assess the regulatory pathway and next steps for Namodenoson following these Phase 2a results.